Viropharma Down 20% After FDA Approves Generic VANCOCIN
Viropharma (NASDAQ: VPHM) is trading lower on the session following the announcement that the FDA has approved Watson Pharmaceuticals's (NYSE: WPI) generic VANCOCIN. The capsules are for the treatment of C. difficile-associated diarrhea and also for the treatment of enterocolitis caused by Staphylococcus aureus.
Viropharma is engaged in the development and commercialization of products that address diseases, with a focus on products used by physician specialists or in hospital settings. The stock is down 18 year-to-date.
The shares of Viropharma are currently trading at $22.65, a loss of $5.97 or 20.85%.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.